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Prazosin an a1-adrenoceptor (AR) antagonist has been shown to reduce liver injury in a mouse model of
non-alcoholic steatohepatitis (NASH) and is suggested as a potential treatment of NASH especially given
its concomitant anti-ﬁbrotic properties. The effect however, of b-AR blockade in non-cirrhotic NASH is
unknown and is as such investigated here. In the presence of the b-blocker propranolol (PRL), mice fed
normal chow or a half methionine and choline deﬁcient diet, supplemented with ethionine (HMCDE),
to induce NASH, showed signiﬁcantly enhanced liver injury, as evidenced by higher hepatic necrosis
scores and elevated serum aminotransferases (ALT). Mechanistically, we showed that murine hepato-
cytes express a and b adrenoceptors; that PRL directly induces hepatocyte injury and death as evidenced
by increased release of lactate dehydrogenase, FASL and TNF-a from hepatocytes in the presence of PRL;
and that PRL activated the apoptotic pathway in primary hepatocyte cultures, as indicated by upregula-
tion of Fas receptor and caspase-8 proteins. The b-AR antagonist PRL therefore appears to enhance liver
injury through induction of hepatocyte death via the death pathway. Further studies are now required to
extrapolate these ﬁndings to humans but meanwhile, b-AR antagonists should be avoided or used with
caution in patients with non-cirrhotic NASH as they may worsen liver injury.
 2013 Published by Elsevier Inc.Open access under CC BY license.1. Introduction The sympathetic nervous system (SNS) appears to be a viableThe prevalence of non-alcoholic fatty liver disease (NAFLD) is
rising worldwide in parallel with increasing rates of obesity [1,2].
At present, about 23–34% of the United States population have
NAFLD: with the population prevalence of the more severe stage
– NASH, estimated at about 2.5% [3]. In the United Kingdom, adult
obesity rates have trebled since 1980 [4] and are predicted to reach
50% by 2050 [5]. The prevalence, moreover, of NAFLD in obese or
diabetic individuals is higher than in the general population and
is estimated at 70–90% [6]. NAFLD deﬁnes a spectrum of liver dis-
eases from fatty liver (steatosis), through fatty liver with inﬂam-
mation (NASH), to cirrhosis and primary liver cancer [2]. Despite
its demographic importance, proven treatments are currently not
available.therapeutic target in NAFLD, as a1-adrenoceptor antagonism with
prazosin (PRZ) has been shown to reduce liver injury, in a model of
NASH [7]. This suggests that the homeostatic effect of SNS signal-
ing on liver repair is inhibitory such that adrenoceptor antagonism
enhanced repair. Furthermore, hepatic ﬁbrogenic stellate cells ex-
press functional adrenoceptors [8–10] and Dbh/ mice lacking
catecholamine SNS neurotransmitters through deletion of the cat-
echolamine synthesizing enzyme dopamine b-hydroxylase as well
as ob/ob mice, which are deﬁcient in leptin with reduced SNS neu-
rotransmitter tone, have impaired ﬁbrogenic responses [8]. These
altogether suggest that adrenoceptor antagonists offer utility as
novel, pro-regenerative, anti-ﬁbrotic, treatments for NAFLD.
Although there is a large body of liver experience with b-AR antag-
onists, such as propranolol (PRL), which are used for treatment of
portal hypertension [11–14], their effect in non-cirrhotic liver, in
NAFLD is not known.
To address this, we used a mouse model of NASH, where we
showed that PRL, unlike prazosin, increased biochemical and histo-
logical evidence of liver injury. We next investigated the mecha-
nisms through which PRL induced liver injury in vitro and
showed that PRL induces liver injury via activation of apoptotic
pathways.
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2.1. Animals
Male, lean C57BL/6 mice, and ob/ob mice, 10–18 weeks old
were from Jackson Laboratory (Bar Harbor, ME). Animals had unre-
stricted access to diets and water. All animal experiments satisﬁed
National and Institutional regulatory guidelines.2.2. Diets and drugs
Control methionine choline diet (CMCD) was purchased from
ICN (Aurora, OH). The injurious diet, also from ICN, contained half
the control amounts of choline and methionine and was adminis-
tered with 0.15% ethionine (Sigma, St. Louis, MO) in drinking
water, previously shown to enhance oxidative injury to the liver
and cause hepatic accumulation of OC [7,15]. The combination
treatment is hereafter referred to as half methionine choline-deﬁ-
cient diet plus ethionine (HMCDE).AL
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Fig. 1. (A, B): PRL increases HPC numbers and markers of liver injury in mice fed norma
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PRL induction of liver injury in mice fed HMCDE.2.3. In vivo experiments
For the in vivo PRL experiments, lean normal mice were divided
into 4 groups (10–12 mice/group) and treated as follows: Normal
chow, NC (control diet); NC plus intra-peritoneal (IP) administra-
tion of PRL (Sigma, St. Louis, MO), at 4 mg/kg/day; HMCDE
diet alone; and HMCDE plus IP administration of PRL, all for
4 weeks. This protocol is essentially as used previously [7].
All mice were weighed at the beginning of the feeding period
and weekly thereafter until sacriﬁce. At sacriﬁce, livers were ﬁxed
in buffered formalin or optimal cutting temperature (OCT) ﬁxative
(Sakura, Torrance, CA) and processed for histology. Alternatively,
liver samples were snap frozen in liquid nitrogen and stored at
80 C for further analysis.2.4. Histology
Sections of liver were prepared for histology and immunochem-
istry as previously described [16,17]. Hematoxylin–eosin-stained
sections were examined by an experienced liver pathologistHMCDE HMCDE+PRL
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and parafﬁn-embedded. In addition, sera were assayed for ALT as a marker of liver
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Fig. 2. Murine hepatocytes express a and b adrenoceptors. RT-PCR of hepatocyte
RNA was used to analyze expression of adrenoceptor mRNA. Results from a
representative analysis are shown. The ﬁrst lane shows the DNA ladder (500–
200 bp). Each subsequent pair of lanes is a replicate analysis of adrenoceptor gene
expression. The 18S band (324 bp) in each lane is shown as a control.
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scored in the following manner: no fat = 0, focal fat accumulation
in <0.1% of the hepatocytes = 1, fat in 1–30% of the hepato-
cytes = 1+, fat in 31–60% of the hepatocytes = 2+, and fat in 61–
100% of the hepatocytes 3+. To evaluate the amount of hepatocyte
necrosis, the number of necrotic hepatocytes was counted in 10
randomly selected ﬁelds with a 20 lens.
2.5. Culture media
All primary cells isolated were grown in either control medium
(DMEM), supplemented with fetal bovine serum (FBS), or a methi-
onine and choline deﬁcient (MCD) medium, as an in vitro equiva-
lent of the in vivo administered HMCDE. The MCD medium has
previously been shown to induce steatosis and injury in the hepa-
tocyte cell line AML-12 [18].
2.6. Isolation and culture of mouse primary hepatocytes
Mouse primary hepatocytes were obtained each time from the
livers of 3 sacriﬁced mice. The livers were gently crushed in the
presence of collagenase type IV (10 lM, Sigma) and DNase
(10 lM, Sigma) in HBSS (Gibco), followed by a 20 min shaking
incubation at 37 C. The homogenate was then ﬁltered, into fresh
tubes, and centrifuged at 500g for 3 min. The supernatant was dis-
carded, the pellet washed with PBS and then re-suspended in red
cell lysis buffer (e-biosciences, San Diego, CA) and incubated at
room temperature for 10 min, followed by centrifugation at 500g
for 3 min. The obtained hepatocytes were re-suspended in 1 mL
of DMEM prior to inoculation into 12 well plates coated with col-
lagen type I (# 35,6700, BD Biosciences, San Jose, CA). Hepatocytes
were cultured either in DMEM with/without FBS, ±PRL or in MCD
with/without FBS, ±PRL.
2.7. Alanine Aminotransferase
Supernatants from primary hepatocyte cultures were analyzed
for Alanine Aminotransferase (ALT) content by our Institutions’
Clinical Chemistry Laboratory.
2.8. Lactate dehydrogenase
Approximately 5  104 primary hepatocytes were inoculated
into each well of a 96 well plate in triplicate. Following appropriate
treatments, each sample was homogenized in lysis buffer, incu-
bated for 10 min (5% CO2, 90%, humidity, 37 C) and the lysates
centrifuged at 600g. 10 ll aliquots of supernatant were then trans-
ferred to a fresh 96 well plate, 100 ll of LDH reaction mixture (Bio-
vision, K313-600) was added and the samples incubated for 30 min
at room temperature after which optical density at 450 nm wasdetermined and LDH concentration extrapolated from a standard
curve.
2.9. TNF-a and FAS-ligand
TNF-a and FASL proteins were quantiﬁed with the Quantikine
sandwich ELISA system (#MTA00 & #MFL00, R&D Systems, Minne-
apolis, MN). Brieﬂy, supernatants from appropriately treated pri-
mary hepatocytes grown in control or MCD media were
centrifuged at 1500 rpm to remove debris and transferred to 96
well plates. 50 ll of supernatant was then incubated in the
presence of a proprietary conjugate and colorimetric substrate as
instructed by the manufacturer. The optical density at 570 nm
was then determined in an Anthos htIII spectrometer and analyte
concentration extrapolated from a standard curve.
2.10. RT-PCR
RNA was isolated from murine hepatocytes using either Trizol
reagents (Invitrogen) or RNeasy kits (Qiagen, Valencia, CA). Con-
centration and purity were assessed by absorbance at 260/
280 nm. RT-PCR was performed with superscript one-step with
platinum Taq kits (Invitrogen, Carlsbad, CA) using Ambion’s Quant-
umRNA Classic II 18S internal standard (Ambion, Austin, TX). Pri-
mer sequences and conditions were as reported [7].
Final PCR products were analyzed both by melting curves and
agarose gel (1%) electrophoresis. The amount of transcript was cal-
culated and expressed as the difference relative to the control gene
GAPDH (2DDCt, where DCt represents the difference in threshold
cycles between the target and control genes) essentially as de-
scribed [7].
2.11. Western blotting
Proteins of the apoptotic pathways were evaluated in primary
hepatocytes after treatments with PRL as described above. Cell
homogenates were prepared and protein content quantiﬁed by
BSA assay (Pierce, Rockford, IL) using bovine serum albumin stan-
dards. Proteins (20 lg/lane) were then resolved by polyacrylamide
gel electrophoresis, transferred to nylon membranes and probed
with the following primary antibodies: caspase-3, #9662; cas-
pase-9, #9509; cytochrome c, #4272 (all supplied by Cell Signal-
ing); caspase-8, AF1650 (R&D Systems), FAS, AF9150 (R&D
Systems), with b-actin, SC-1616 (Santa Cruz Biotechnology, Santa
Cruz, CA) as a control.
Horseradish peroxidase-conjugated secondary antibodies, SC-
2031 (Santa Cruz Biotechnology) detected primary antibodies
and antigens were demonstrated by enhanced chemiluminescence
(Amersham Pharmacia Biosciences, Piscataway, NJ).
2.12. Statistical analysis
All values are expressed as mean ± SEM. Group means were
compared by unpaired t-test or ANOVA using Graphpad Prism
3.03 (San Diego, CA). Signiﬁcance was accepted as p < 0.05.
3. Results
3.1. PRL induces liver injury in NC or HMCDE fed mice
PRZ is known to induce expansion of HPC and reduce liver in-
jury in HMCDE fed mice [7]. To determine whether b-blockade
with PRL induced a similar reduction of injury, livers of PRL treated
animals were examined for extent of injury. As shown in Fig. 1A,
mice fed NC diet had normal levels of ALT (about 40 IU/ml),
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Fig. 3. (A, B, C): PRL induces hepatocytes injury in vitro. Mouse primary hepatocytes were cultured for 12 h in control media, MCD deﬁcient or serum free (SF) media to
simulate NASH in vitro, in the presence or absence of PRL. At completion LDH was analyzed. As shown (A) PRL treatment induces hepatocyte injury, reﬂected by release of
LDH in both control and or MCDmedia. As conﬁrmation of induction of death inducing pathways we also assayed FASL and TNF-a after hepatocyte culture in control medium.
As shown in (B), PRL induced release of the pro-apoptotic proteins FASL and TNF-a from cultured primary hepatocytes. Analysis of the apoptotic pathway proteins in the
presence of PRL showed that in MCD media, PRL drives hepatocyte apoptosis via the upregulation of FAS, caspase-8 and cytochrome c (C).
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500 IU/ml. PRL signiﬁcantly increased serum ALT in both NC and
HMCDE fed groups (up to 75 and 725 IU/L respectively). Histolog-
ical examination of the livers in the two groups conﬁrmed that PRL
markedly enhanced liver injury (Fig. 1B).3.2. Murine hepatocytes express a and b adrenoceptors
To study the differential effects of PRZ and PRL on liver injury in
the context of NASH, we ﬁrst assayed the presence of adrenocep-
tors on hepatocytes. Adrenoceptors are known to be expressed in
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and the subtypes therein is not known. Hepatocytes were shown
here to express a1B and b2 adrenoceptors (Fig. 2).
3.3. PRL directly induces hepatocyte injury
The increase in liver damage engendered by PRL suggested that
PRL treatment in the context of NASH may directly induce hepato-
cyte injury. To conﬁrm this possibility, mouse primary hepatocytes
were cultured in control or MCD media (in order to simulate NASH
in vitro) [18], in the presence or absence of PRL. Hepatocyte injury
was assessed by assaying released LDH.
LDH release was signiﬁcantly increased by PRL or serum free
(SF) media with control or MCD media (Fig. 3A).
3.4. PRL induces release of FASL and TNF-a from hepatocytes
Since PRL increased hepatocyte death, we next sought to deter-
mine whether the pro-apoptotic proteins TNF-a and FASL were re-
leased into the culture medium in the presence of PRL. Both
proteins act as ligands for the initiation of the apoptotic pathway
by interacting with the death receptor, FAS [21,22]. We show here
a robust release of FASL from hepatocytes cultured with PRL
(10 lM) (Fig. 3B). Release of TNF-a, assayed as an alternative
pro-apoptotic protein, was similarly enhanced by PRL (Fig. 3B).
3.5. PRL treatment induces hepatocyte apoptosis via the apoptotic
pathways
Since PRL induced death ligands release as shown above, we
next studied involved death pathways. Primary murine hepato-
cytes were again cultured in control or MCDmedium with or with-
out PRL. Cell lysates were then analyzed for changes in expression
of proteins involved in the apoptotic pathway.
The apoptotic effector protein caspase-3 was activated in both
the PRL and SF treated cells, in control or MCD media, indicating
that an apoptotic program of death is induced by treatment with
PRL (Fig. 3C). PRL treated groups displayed prominent levels of
the apoptotic pathway death receptor Fas (Fig. 3C). Similarly, death
receptor dependent protein caspase-8 was activated, as judged by
the appearance of its cleavage products (43/41 kDa). The effect was
observed equally in control and MCD media.
Cytochrome c was not readily detected after hepatocyte culture
in control medium, but considerable levels were observed in MCD
media after PRL treatment or under SF conditions (Fig. 3C). Simi-
larly, the reduction of caspase-9 from its inactive pro-form to ac-
tive form was only observed in MCD media (Fig. 3C). Thus, PRL
promotes hepatocyte death via the apoptotic pathway under con-
ditions, which more closely mimic the in vivo situation in NASH.4. Discussion
Currently, the most prevalent chronic liver disease in afﬂuent
countries is NAFLD but despite its clear demographic importance,
there are no proven treatments, reﬂecting lack of understanding
of the mechanisms underlying the disease.
Our previous studies have shown that the a1-adrenoceptor
antagonist, PRZ, reduced liver injury in a mouse model of NASH
[7]. SNS signaling appears to also be regulating hepatic ﬁbrogenesis
through effects on hepatic ﬁbrogenic cells [8,9,23], which offers the
prospect that adrenoceptor antagonists may be used as pro-regen-
erative, anti-ﬁbrotic agents in liver disease. This prospect is allur-
ing because there is extensive clinical experience in liver disease,
with b-adrenoceptor antagonists, such as PRL, which are widely
used as treatments for portal hypertension [11,12]. Our hypothesishere was that PRL would as with PRZ reduce liver injury. If our
hypothesis was proven, SNS antagonism with PRL as a novel, early,
pro-regenerative treatment for NAFLD and potentially other liver
diseases could easily be translated to the clinic because of the vast
experience with this and other b-adrenoceptor antagonists and
their low cost compared to putative cytokine or cell based
therapies.
We tested our hypothesis by ﬁrst studying the effect of the b-
adrenoceptor antagonist, PRL in a murine model of NASH.
Biochemical evidence of liver injury was determined by assaying
ALT release and conﬁrmed by histological evaluation for necrosis
and steatosis. Our results show that PRL, unlike PRZ, increased bio-
chemical and histological markers of liver injury and cell death, un-
der conditions simulating NASH.
To ascertain whether PRL induced hepatocyte death and to ana-
lyze the mechanisms therein, primary hepatocytes were ﬁrst con-
ﬁrmed to express adrenoceptors. Hepatocytes were then cultured
in a medium deﬁcient in methionine and choline, to simulate
in vitro, the in vivo conditions of increased oxidant stress that oc-
cur with NASH, which replicates the HMCDE murine model of
NASH. These studies conﬁrmed that PRL, in vitro as well, induced
hepatocyte death as evidenced by increased release of LDH, TNF-
a and FAS ligand. To then determine the pathways induced by
PRL, we studied factors from the apoptotic pathway. In control
media, PRL induced death predominantly via the upregulation of
Fas receptor and caspase-8 proteins, whereas in MCD deﬁcient
media, PRL similarly induced death through upregulation of FAS,
caspase-8 as well as cytochrome c, which was not upregulated in
the control group.
Therefore our starting hypothesis that PRL similar to PRZ would
reduce liver injury was not correct. PRL increased liver injury in
mice fed NC but more so in animals fed a NASH simulating HMCDE
diet through activating the apoptotic pathway in hepatocytes.
Moreover, the b-AR antagonist, PRL, whilst useful for portal hyper-
tension may be detrimental to the liver in the absence of portal
hypertension, in NASH. As such, a-adrenoceptor but not b-AR
antagonists offer novel clinical utility as pro-regenerative, anti-ﬁ-
brotic therapeutic agents in NAFLD. These ﬁndings are clinically
signiﬁcant in the increasing population of patients with metabolic
syndrome and obesity, who have ischemic heart disease and are
placed on b-blockers but may concurrently have undeclared NASH.
Further studies in animals and humans are required to study the
effects of b-blockers in the context of NAFLD and NASH. Mean-
while, b-AR antagonists should be avoided or used with caution
in individuals with NASH to prevent worsening liver injury.
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